

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Use of silibinin, its salts and/or its pro-drugs with  $\alpha$ -lipoic acid, its salts and/or its pro-drugs for the production of a medicine for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases.
2. (Original) Use according to claim 1, characterised in that the dose of the  $\alpha$ -lipoic acid, its salts and/or its pro-drugs for administration to a human patient is between 30 and 1800 mg/d, preferably between 200 and 600 mg/d.
3. (Currently Amended) Use according to ~~one of claims 1 or 2~~ Claim 1, characterised in that the dose of silibinin, its salts and/or its pro-drugs for administration to a human patient is between 20 and 1600 mg/d, preferably between 300 and 800 mg/d.
4. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that the medicine can be administered by inhalation, orally or parenterally.
5. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that the medicine contains further additives selected from the group of aqueous solvents, stabilisers, suspending, dispersing and wetting agents.
6. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that the medicine is presented in the form of an aerosol, a solution, granules, a powder, an emulsion, a tablet and/or a film tablet.
7. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that silibinin, its salts and/or its pro-drugs and the  $\alpha$ -lipoic acid, its salts and/or its pro-drugs are presented in a single formulation.
8. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that silibinin, its salts and/or its pro-drugs and the  $\alpha$ -lipoic acid, its salts and/or its pro-drugs are presented in separate formulations.
9. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that the medicine is presented in the form of an aerosol, a solution, granules, a powder, an emulsion, a tablet and/or a film tablet.
10. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that the effector of glutathione metabolism and the  $\alpha$ -lipoic acid, its salts and/or its pro-drugs are presented in a single formulation.

11. (Currently Amended) Use according to ~~at least one of the preceding claims~~ Claim 1, characterised in that the effector of glutathione metabolism and the  $\alpha$ -lipoic acid, its salts and/or its pro-drugs are presented in separate formulations.
12. (New) A method for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases comprising administering silibinin, its salts and/or its pro-drugs with  $\alpha$ -lipoic acid